The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Subscribe To Our Newsletter & Stay Updated
